Evidence map›Paper›PMID 26703564›Full record

ArticleInternational journal of molecular sciences2015

High SPARC Expression Starting from Dysplasia, Associated with Breast Carcinoma, Is Predictive for Bone Metastasis without Enhancement of Plasma Levels.

Paola Maroni, Paola Bendinelli, Daniele Morelli, Lorenzo Drago, Alessandro Luzzati, Giuseppe Perrucchini, Chiara Bonini, Emanuela Matteucci, Maria Alfonsina Desiderio

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Paola MaroniIstituto Ortopedico Galeazzi, Scientific Institute for Research, Hospitalization and Helth Care (IRCCS), 20161 Milano, Italy. paola.maroni@grupposandonato.it.
Paola BendinelliDipartimento di Scienze Biomediche per la Salute, Molecular Pathology Laboratory, Università degli Studi di Milano, 20133 Milano, Italy. paola.bendinelli@unimi.it.
Daniele MorelliDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy. daniele.morelli@istitutotumori.mi.it.
Lorenzo DragoIstituto Ortopedico Galeazzi, Scientific Institute for Research, Hospitalization and Helth Care (IRCCS), 20161 Milano, Italy. lorenzo.drago@unimi.it.
Alessandro LuzzatiIstituto Ortopedico Galeazzi, Scientific Institute for Research, Hospitalization and Helth Care (IRCCS), 20161 Milano, Italy. sandroluzzati@tiscali.it.
Giuseppe PerrucchiniIstituto Ortopedico Galeazzi, Scientific Institute for Research, Hospitalization and Helth Care (IRCCS), 20161 Milano, Italy. pergiudoc@yahoo.com.
Chiara BoniniDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy. chiara.bonini@istitutotumori.mi.it.
Emanuela MatteucciDipartimento di Scienze Biomediche per la Salute, Molecular Pathology Laboratory, Università degli Studi di Milano, 20133 Milano, Italy. emanuela.matteucci@unimi.it.
Maria Alfonsina DesiderioDipartimento di Scienze Biomediche per la Salute, Molecular Pathology Laboratory, Università degli Studi di Milano, 20133 Milano, Italy. a.desiderio@unimi.it.
University of Milan · ITIstituto Ortopedico Galeazzi · ITFondazione IRCCS Istituto Nazionale dei Tumori · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to become established in the skeleton, metastatic cells disseminating from the breast carcinoma need to acquire organ-specific traits. There are no effective predictors for who will develop bone metastasis to guide long-term predictive therapy. Our purpose was to individuate events critical for bone colonization to make a molecular classification of breast carcinoma useful for bone-metastasis outcome. In dysplasia adjacent to carcinoma and in pair-matched specimens of bone metastasis we examined SPARC expression and localization as well as Endothelin 1/ETAR signals by immunohistochemistry, and the evaluation of plasma levels of SPARC by ELISA was also performed. In patients with breast carcinoma metastasizing to bone, SPARC and Endothelin 1/ETAR axis were highly expressed from dysplasia until bone metastasis, but the SPARC plasma level was as low as that of normal women, in contrast to patients that never develop bone metastasis, suggesting that circulating SPARC was counter adhesive. Altogether, the early identification of SPARC/Endothelin 1/ETAR in dysplastic lesions would be important to devise therapies preventing metastasis engraftment, since often carcinoma cells spread to distant organs at the time or even before patients present with cancer.

Indexed as

AdultBiomarkers, TumorBone NeoplasmsBreast NeoplasmsCarcinomaCase-Control StudiesEndothelin-1FemaleHumansMiddle AgedOsteonectinReceptor, Endothelin ABiomarkers, TumorEndothelin-1OsteonectinReceptor, Endothelin ASPARC protein, humanbone metastasisbreast carcinomadysplasiaEndothelin 1ETARSPARC

Identifiers

PMID26703564
PMCPMC4691022
OpenAlexW2172335536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.